SHS Capital Acquires Majority Stake in Basic Pharma

SHS Capital, a specialist in healthcare investments, has acquired a majority stake in Basic Pharma, a leading Dutch pharmaceutical CDMO and dossier developer. This strategic move aims to facilitate a structured succession for Basic Pharma's founder, Bob Kool, while accelerating the company's growth and international expansion. The transaction is expected to finalize shortly.

Basic Pharma, known for its nasal sprays and semi-solid pharmaceuticals, has a strong market position in Europe. Its integrated "licence & supply" model stands out, aligning product development with proprietary dossier ownership and GMP manufacturing. The firm has witnessed significant growth due to increasing demand for its products and maintains a loyal customer base of distributors and generic pharmaceutical companies.

SHS Capital's involvement is expected to bolster Basic Pharma's operational excellence and professionalization, with plans to pursue selective acquisitions in the fragmented European CDMO landscape. Bob Kool will remain actively involved, supporting the company in an advisory capacity.